Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

HCV diagnosed incident cases will substantially increase following updated guidelines

According to new guidelines published by the US Preventive Services Task Force (USPSTF), hepatitis C virus (HCV) screening will now expand to include all adults ages 18 to 79 years, effectively replacing the 2013 recommendations which limited screening to only high-risk individuals and adults born between 1945 and 1965. With the expanded screening criteria, the number of truly diagnosed incident cases will substantially increase over the […]
Read more

COVID-19 social distancing measures will impede global RSV clinical development, says GlobalData

Following the introduction of social distancing measures, brought in to reduce the spread of COVID-19 across the globe; Emily Carter-Richardson, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on how this could impact the development of respiratory syncytial virus (RSV) vaccines: “The infection control measures of social distancing to prevent […]
Read more

Alexion to start Soliris in COVID-19 Phase II trial in next few days, says GlobalData

Alexion Pharmaceuticals is revving up to enter the COVID-19 drug development race with Soliris (eculizumab), a drug that is already approved for other indications, a source familiar with the trial told Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Castañeda comments: “The source explained that the idea behind Soliris […]
Read more

US COVID-19 cases projected to increase 65% as risk of transmission likely to surpass Italy and Spain, says GlobalData

In the key markets most heavily affected by the coronavirus (COVID-19), case trends are expected to follow a low-risk forecast, with the exception of the US, according to GlobalData, a leading data and analytics company. Natasha Karim, Managing Epidemiologist at GlobalData comments: “Most countries have enforced strict quarantine and mitigation measures. As a result, confirmed […]
Read more

Combination therapies could help overcome limitations of ICIs for oncology indications, says GlobalData

While checkpoint inhibitors as monotherapies have fulfilled expectations in some indications, novel combinations are on the horizon in a broader range of cancers says GlobalData, a leading data and analytics company. The company’s latest report, ‘Immuno-oncology: Focus on Development and Opportunities in Immune Checkpoint Modulators’, reveals that developers are investigating new checkpoint targets to overcome some […]
Read more

COVID-19 pandemic has multitude of implications for cardiovascular and metabolic disorder space, says GlobalData

COVID-19 has a significant impact on patients with pre-existing conditions, many of which fall under the cardiovascular (CV) and metabolic disorder (CVMD) category. The current uncertainty regarding treatment with certain CV drugs, the supply chain and clinical trials is also notable. Overall, the pandemic is already impacting the CVMD healthcare landscape, and leading data and […]
Read more

Intarcia’s ITCA 650 unlikely to reach diabetes market following second FDA rejection

Following the news that Intarcia has received a second rejection from the Food and Drug Administration (FDA) regarding its subcutaneous osmotic pump implant, ITCA 650, for type 2 diabetes (T2D) patients; Akash Patel MSc, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “This second FDA rejection leaves the future of Intarcia and its device highly uncertain and it is unlikely that its product will be able to reach the market. Even if ITCA 650 were to make it to market, […]
Read more

75% of nanopharmaceuticals are in clinical development for oncology indications

Of the more than 230 nanopharmaceuticals in clinical development, 75% are for oncology indications, including many hard-to-treat cancers with few treatment options, according to GlobalData, a leading data and analytics company. Nanopharmaceuticals have many physical and biological advantages compared to conventional medicines, including enhanced efficacy and reduced toxicity, which are particularly important in treating cancer patients. One of the main areas of opportunity for nanomedicine to date has been oncology, with high levels of research and development (R&D) activity detected in the field.  GlobalData’s recent report, […]
Read more
,

Coronavirus is prompting suppliers of all shapes and sizes to adapt and support the healthcare system

Thus far, the novel coronavirus (COVID-19) pandemic has surpassed 860,000 confirmed cases globally and while the economic impact is weighing heavily across sectors, organizations are exploring creative ways of how to combat the outbreak. The responses are not only fighting COVID-19, supporting the general public and propping up the healthcare system, but they are also positioning suppliers favorably for the aftermath, says GlobalData, a leading data and analytics company. Organizations across various industries worldwide are pivoting in response to both the clinical and socio-economic effects of COVID-19 to help their local communities. For example, retailers are finding ways of dealing with high demand, […]
Read more

Coronavirus pandemic pushes pharma sales reps deeper into virtual space, says GlobalData

As the novel coronavirus (COVID-19) pandemic continues to spread globally, virtual platforms will experience an extra boost after already having a transformational impact on the entire healthcare landscape even before the outbreak, says GlobalData, a leading data and analytics company. Valentina Gburcik, PhD, Senior Director of Cardiovascular and Metabolic Diseases, Gender Health and Digital at […]
Read more

VIRAL LOAD and COVID-19: how concerned should we be? asks GlobalData

Following a number of recent global news stories about viral load and its impact on Coronavirus (COVID -19) patients; Michael Breen, Director of Infectious Diseases at GlobalData, a leading data and analytics company, offers his view on this phenomena and how concerned we should be about it; “A recent study from China supports a higher viral […]
Read more

Significant unmet needs remain in the global psoriatic arthritis market

Despite the plethora of drugs currently available for patients with psoriatic arthritis (PsA), several key unmet needs remain, according to GlobalData, a leading data and analytics company. The company’s report: ‘Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028’ reveals that the PsA market was worth over $4.6bn in 2018 and is set to grow to $9.4bn by 2028. Key unmet needs in the disease space include increased clinician awareness, earlier PsA diagnoses, improved drug safety and efficacy across all disease domains […]
Read more
1 … 99 100 101 102 103 … 110